"Now turning to our full year 2021 guidance on Slide 35. We expect sales to grow low to mid-single-digit and core operating income to grow mid-single digit, ahead of sales driving core margin increase. Within the divisions, we expect Innovative Medicines sales to grow mid-single-digit and Sandoz top line to be broadly in line with the prior year."